T2 Biosystems, Inc.: Nasdaq/NYSE listing notice — T2 Biosystems receives Nasdaq delisting notice for MVLS below $35M minimum

T2 Biosystems, Inc.

Received Nasdaq deficiency letter on Nov 22, 2022 for MVLS < $35M for 30 consecutive business days.
Has 180 days, until May 22, 2023, to regain compliance under Nasdaq Listing Rule 5550(b)(2).
Can regain compliance if MVLS closes at $35M+ for 10 consecutive business days.
No immediate effect on listing or trading of common stock; delisting possible if not cured.
Company may consider extension or appeal to Nasdaq Hearings Panel if non-compliance persists.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

November 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until May 22, 2023, to regain compliance. The letter states that the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-292611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.